trials
This is particularly relevant for entrepreneurs. The landscape today is not anymore the one in which Elizabeth Holmes was able to pull a “Ana Delvey” on an impressive list of investors to grow her venture to a $10B valued unicorn. Investors today are evidence-driven and data-driven. The promises have to be substanciated with a solid process BEFORE the later series of investment. Even at seed level, there are significant expectations in terms of clinical evidence.